is supported by the European
Union through the “Technology
Transfer Pilot Project”
The roots of Karolinska Development date back to 2003. At this time, Karolinska Institutet – one of Europe’s largest medical universities and Sweden’s largest center for medical training and research – initiated a system to secure financing for the many innovations coming from its researchers.
Initial investments took place through Karolinska Development I and Karolinska Development II, formed in 2003 and 2005, respectively.
Over a short period of time these companies demonstrated their ability to advance life science innovations towards commercially viable products, both at a competitive pace and in a highly cost-efficient manner. In 2008, the companies were merged into Karolinska Development, which was formed in 2006.
In contrast to the previous companies, Karolinska Development has the potential for far greater flexibility to grow business opportunities and to achieve the optimum exit point for both owners and innovators.
Since 2003, Karolinska Development's portfolio has evolved from projects mainly in lead optimization phase into a balanced portfolio of pharmaceutical development projects in all phases from discovery to Phase II. During these years, the portfolio has grown from 15 projects to 34. At the same time, a few technology projects have reached the market. The portfolio is particularly strong in the areas of cancer, infections and wound healing, inflammation, cardiovascular disease, women's health and diseases that affect the central nervous system.
Portfolio development overview
The portfolio has increased from a total of 15 projects in 2003 to 33projects as of today.
Significant progress has also been made in advancing projects into clinical phase, from four
projects in 2007 to todays 16.